Esketamine (Spravato) is Therapeutic Goods Administration (TGA) approved treatment for Treatment Resistant Depression which is defined as depression that persists despite adequate trials of two or more antidepressants.
Spravato is a nasal spray form of ketamine and has been shown to be safe and effective in the treatment of severe depression. However, it is a restricted medication and can only be delivered at certified treatment centers, like Mindsight Clinic. As of 1 May 2025, Spravato was PBS listed and now subsidised for patients who meet relevant criteria.
If you think this treatment might be suitable for you, please discuss this with your treating psychiatrist or GP.
*Esketamine can only be accessed with a referral from a current treating psychiatrist. If you do not have a treating psychiatrist, you will need to discuss this with your GP
To find out more about Spravato, please download the patient guide here:
Spravato Patient Guide (pdf)
DownloadPlease submit this referral form if you would like to refer a patient for an assessment for Esketamine treatment
REFERRAL FOR ESKETAMINE THERAPY (pdf)
Download(c) Mindsight Clinic 2024
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.